150 related articles for article (PubMed ID: 15930360)
1. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with Cisplatin in solid tumors.
Li G; Tian L; Hou JM; Ding ZY; He QM; Feng P; Wen YJ; Xiao F; Yao B; Zhang R; Peng F; Jiang Y; Luo F; Zhao X; Zhang L; Zhou Q; Wei YQ
Clin Cancer Res; 2005 Jun; 11(11):4217-24. PubMed ID: 15930360
[TBL] [Abstract][Full Text] [Related]
2. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma.
Zhang R; Tian L; Chen LJ; Xiao F; Hou JM; Zhao X; Li G; Yao B; Wen YJ; Li J; Zhang L; Chen XC; Luo F; Peng F; Jiang Y; Wei YQ
Gene Ther; 2006 Sep; 13(17):1263-71. PubMed ID: 16672984
[TBL] [Abstract][Full Text] [Related]
3. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
4. Systemic inhibition of tumor growth by soluble Flk-1 gene therapy combined with cisplatin.
Wang R; Zhang XW; Wang GQ; Chen XC; Tian L; Yang HS; Hu M; Peng F; Yang JL; He QM; Zhang W; Jiang Y; Deng HX; Wen YJ; Li J; Zhao X; Wei YQ
Cancer Gene Ther; 2006 Oct; 13(10):940-7. PubMed ID: 16799469
[TBL] [Abstract][Full Text] [Related]
5. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.
Yap R; Veliceasa D; Emmenegger U; Kerbel RS; McKay LM; Henkin J; Volpert OV
Clin Cancer Res; 2005 Sep; 11(18):6678-85. PubMed ID: 16166447
[TBL] [Abstract][Full Text] [Related]
6. [Experimental studies on anti-tumor effects of BLC-modified tumor cell vaccine combined with cisplatin].
Zou CH; Tian L; Wei YQ; Zhao X; Kan B; Yang JL; Mao YQ; Wen YJ; Li J; Deng HX
Ai Zheng; 2004 Jan; 23(1):1-7. PubMed ID: 14720366
[TBL] [Abstract][Full Text] [Related]
7. Liposomal quercetin efficiently suppresses growth of solid tumors in murine models.
Yuan ZP; Chen LJ; Fan LY; Tang MH; Yang GL; Yang HS; Du XB; Wang GQ; Yao WX; Zhao QM; Ye B; Wang R; Diao P; Zhang W; Wu HB; Zhao X; Wei YQ
Clin Cancer Res; 2006 May; 12(10):3193-9. PubMed ID: 16707620
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
Goto H; Yano S; Matsumori Y; Ogawa H; Blakey DC; Sone S
Clin Cancer Res; 2004 Nov; 10(22):7671-6. PubMed ID: 15570000
[TBL] [Abstract][Full Text] [Related]
9. [Antitumor effects of recombinant quail vascular endothelial growth factor receptor 2, as a vaccine, combined with cisplatin on LL/2 tumor model in mice].
Hou JM; Liu JY; Yang L; Zhao X; Tian L; Lei S; Mao YQ; Wen YJ; Wei YQ
Ai Zheng; 2005 Apr; 24(4):391-6. PubMed ID: 15820058
[TBL] [Abstract][Full Text] [Related]
10. [Improved therapeutic effectiveness by combining recombinant human RhoB with low-dose cisplatin in human lung cancer in nude mice].
Hu XH; Wu WF; Qing Y; Song LF; Huang W; Wu Y; Li Y; Wu XH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jul; 42(4):475-9. PubMed ID: 21866629
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of antitumor chemotherapy in C3H mice enhanced by the antiangiogenesis steroid, cortisone acetate.
Lee K; Erturk E; Mayer R; Cockett AT
Cancer Res; 1987 Oct; 47(19):5021-4. PubMed ID: 2441860
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth.
Ghosh S; Maity P
Int Immunopharmacol; 2006 Oct; 6(10):1550-9. PubMed ID: 16919827
[TBL] [Abstract][Full Text] [Related]
13. Antitumor interaction of short-course endostatin and ionizing radiation.
Hanna NN; Seetharam S; Mauceri HJ; Beckett MA; Jaskowiak NT; Salloum RM; Hari D; Dhanabal M; Ramchandran R; Kalluri R; Sukhatme VP; Kufe DW; Weichselbaum RR
Cancer J; 2000; 6(5):287-93. PubMed ID: 11079167
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
Blakey DC; Westwood FR; Walker M; Hughes GD; Davis PD; Ashton SE; Ryan AJ
Clin Cancer Res; 2002 Jun; 8(6):1974-83. PubMed ID: 12060643
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of recombinant methioninase in combination with cisplatin on human colon tumors in nude mice.
Tan Y; Sun X; Xu M; Tan X; Sasson A; Rashidi B; Han Q; Tan X; Wang X; An Z; Sun FX; Hoffman RM
Clin Cancer Res; 1999 Aug; 5(8):2157-63. PubMed ID: 10473100
[TBL] [Abstract][Full Text] [Related]
16. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
[TBL] [Abstract][Full Text] [Related]
17. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
[TBL] [Abstract][Full Text] [Related]
18. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization.
Schiller JH; Bittner G
Clin Cancer Res; 1999 Dec; 5(12):4287-94. PubMed ID: 10632372
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antitumor effect of CXCL10 with hyperthermia.
Chen P; Yang LL; Yang HS; Wang YS; Li G; Wu Y; Fang F; Liu K; Li J; Zhao X; Hu HZ; Wei YQ
J Cancer Res Clin Oncol; 2008 Jun; 134(6):679-87. PubMed ID: 18066596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
